TsITOKINY: UChASTIE V PATOGENEZE I PERSPEKTIVY LEChEBNOGO PRIMENENIYa PRI BRONKhIAL'NOY ASTME

Tat'yana Vadimovna Borisova , A V Karaulov , Sergey Ivanovich Sokurenko

Journal of Clinical Practice ›› 2010, Vol. 1 ›› Issue (2) : 81 -87.

PDF
Journal of Clinical Practice ›› 2010, Vol. 1 ›› Issue (2) : 81 -87. DOI: 10.17816/clinpract1281-87
Articles
review-article

TsITOKINY: UChASTIE V PATOGENEZE I PERSPEKTIVY LEChEBNOGO PRIMENENIYa PRI BRONKhIAL'NOY ASTME

Author information +
History +
PDF

Cite this article

Download citation ▾
Tat'yana Vadimovna Borisova, A V Karaulov, Sergey Ivanovich Sokurenko. TsITOKINY: UChASTIE V PATOGENEZE I PERSPEKTIVY LEChEBNOGO PRIMENENIYa PRI BRONKhIAL'NOY ASTME. Journal of Clinical Practice, 2010, 1(2): 81-87 DOI:10.17816/clinpract1281-87

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Kips J.C. Cytokines in asthma. ERS Journals Ltd 2001.

[2]

Desai D., Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clinical and Experimental Immunology, 2009 158: 10-19.

[3]

Кетлинский С.А., Симбирцев А.С. Цитокины, Спб, 2008

[4]

Buc M. et al. Immunopatogenesis of bronchial asthma. Arch Immunol ther exp, 2009

[5]

Yui-Hsi Wang, Yong-Jun Liu The IL-17 cytokine and their role in allergic inflammation Current opinion in Immunology, 2008

[6]

Barret N, Austen KF Innate cells and T Helper 2 Immunity in airway inflammation, Immunity, 2009

[7]

Lloyd C. M.,Hawrylowicz C. M. Regulatory T cells in asthma. Immunity. 2009 Sep 18;31(3):438-49

[8]

Holgate S Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease Cytokine, 2004.

[9]

O’Byrne P, Cytokines or their Antagonists for the treatment of asthma. Chest, 2006

[10]

Haldar et al. Mepolizumab and exacerbationsa of eosinofilic refractory asthma. N Engl J Med 2009; 360: 973-84

[11]

Borish LC et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 1816-23;

[12]

Wenzel S, et al. Effect of an IL-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-31

[13]

Holgate S, Novel targets of therapy in asthma, Current opinion in pulmonary medicine, 2009

[14]

Desai D, Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? The journal of Translational Immunology, 2009.

[15]

Wenzel SE, Barnes PJ et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma Am J Respir Crit Care Med 2009; 179:549-58.

[16]

Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol. 2007 Jun;7(3):279-8.

[17]

Brightling C , Berry M, Amrani Y. Targeting TNF-α: a novel therapeutic approach for asthma. J Allergy Clin Immunol, 2008

RIGHTS & PERMISSIONS

Borisova T.V., Karaulov A.V., Sokurenko S.I.

AI Summary AI Mindmap
PDF

42

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/